Sirtex profit grows 30% in FY14
Sirtex Medical (ASX:SRX) grew its net profit for the financial year ending in June by 30.6% to $23.9 million, thanks to higher sales of its SIR-Spheres liver cancer treatment microspheres.
Sales revenue grew 33.7% to a record $129.4 million, with dose sales increasing to 8561 - another company record.
SIR-Spheres deliver targeted radiation therapy to liver cancers. The product is on sale in the Americas, EMEA and Asia-Pacific.
Revenue from the Americas grew 37.4% to $96 million, thanks to a 22.5% increase in dose sales. EMEA sales were up 24.6% to $27.7 million, but dose sales increased a slimmer 5.6%. APAC revenue increased 20.9% to $5.7 million and dose sales grew 12.4% to 809 units.
Sirtex CEO said the company had delivered “another solid result” during the financial year. “We believe our current growth rate is sustainable. However, a positive result from our clinical studies should see an acceleration or step change in our growth.”
The company is currently engaged in the multi-year Sirflox marketing study and expects the results from the trial to help convince more clinicians to take up SIR-Spheres as a first-line treatment for liver cancer.
The study completed recruitment in April 2013, and results are expected to be released in 2015.
Sirtex Medical (ASX:SRX) shares were trading 0.2% lower at $20.00 as of around 2 pm on Wednesday.
Lead exposure linked to memory problems, even decades later
Historic lead levels from the era of leaded petrol may be contributing to cognitive issues 50...
New vulnerability found in the aging brain
An international research team has discovered that in the aging brain, certain proteins are lost...
Genetic weak spot found in hard-to-treat cancers
Research shows that blocking minor splicing can markedly slow tumour growth in liver, lung and...
